INTRODUCTION

Chronic lymphocytic leukemia (CLL) involves the monoclonal expansion of CD5
+ B lymphocytes in the bone marrow, peripheral blood, and lymphoid organs (1) . Most patients present with an indolent disease and may not require treatment for many years, whereas a minority of patients (about 30%) display a rather aggressive disease course requiring early treatment. Clinical heterogeneity may be attributed to both clone-intrinsic biological features and clone-extrinsic events, given the fact that signals from the surrounding microenvironment are increasingly recognized as determinants of clone fitness and progression (2) (3) (4) (5) .
The mechanisms underlying CLL cell clonal expansion are only partially understood. In vivo cell kinetic studies in patients have demonstrated that CLL cells have a substantially higher proliferative rate than originally estimated, which challenged the view that the CLL clone endorses minimal proliferative capacity despite conspicuous resistance to cell death (6, 7) . Proliferation of CLL cells occurs primarily in peripheral lymphoid organs, specifically within the so-called proliferating centers of infiltrated lymphoid tissues, and is driven by signals delivered by the surrounding cells, by cytokines, and even by the CLL cell B cell receptor (BCR) (8) (9) (10) . Furthermore, proinflammatory cytokines have been variably demonstrated to identify CLL subsets having more aggressive disease and worse survival (11, 12) . Finally, many CLL clones express BCR with polyreactivity and/or self-reactivity, which could bind (although with low affinity) to a number of self-antigens expressed by surrounding cells, contributing to their activation and subsequent susceptibility to growth signals (13, 14) . Likewise, a similar function may be exerted by the recognition of antigens exposed by apoptotic cells or of internal epitopes of the CLL BCR itself (15) (16) (17) (18) .
Interleukin-23 (IL-23) is a pleiotropic cytokine of the IL-6 superfamily involved in the bridging of adaptive and innate immunity and in tissue remodeling (19) . IL-23 is a heterodimeric cytokine composed of a p19 subunit and a p40 subunit, which is common to IL-12. IL-23 is predominantly produced by myeloid dendritic cells and type 1 macrophages in response to microbial or host immune stimuli and is involved in the regulation of immune responses against infections and tumor development through the engagement of the IL-23 receptor (IL-23R) (20) (21) (22) . The IL-23R is a heterodimeric complex consisting of an IL-12R1 chain (also common to the IL-12R) and a specific IL-23R subunit (22) . To date, the demonstration of functional IL-23R complex expression in normal B cells has been confined to early B lymphocytes, germinal center B cells, and plasma cells (23, 24) . The IL-23R heterodimer is also expressed by acute lymphoblastic leukemia (ALL) cells, follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and myeloma cells (23) (24) (25) (26) .
Here, we demonstrate that circulating CLL cells of early-stage, Binet A patients variably express the IL-23R subunit in the absence of the IL-12R1 chain and that the expression of the IL-23R subunit positively correlates with adverse prognostic factors and a higher risk of therapy need. We also provide evidence of a regulation of the IL-23R complex by the microenvironment and unveil an autocrine/paracrine loop involving IL-23R complex up-regulation and IL-23 synthesis in CLL clones. Finally, we demonstrate that this loop may represent a therapeutic target because in vivo treatment with an anti-IL-23p19 monoclonal antibody (mAb) (IL-23p19) eradicated CLL clones in xenografted mice.
RESULTS
Uncoupled IL-23R expression characterizes circulating peripheral CLL cells and identifies high-risk early-stage patients
The surface expression of the two chains of the IL-23R complex (IL-23R and IL-12R1 subunits) was investigated in circulating CLL cells of 57 consecutive Binet stage A patients enrolled in a multicenter prospective trial. Although the expression of the IL-23R chain varied from high to low ( + cells) from all the peripheral blood mononuclear cell (PBMC) suspensions analyzed (Fig. 1C) . The uncoupled expression of IL-23R and IL-12R1 side chains was also confirmed by double-marker immunofluorescence (IF) studies using cytospin preparations (Fig. 1B) . IL-23R was expressed by T cells and natural killer (NK) cells from the same CLL cases, which also showed a substantial proportion of IL-12R1 + cells (see Fig. 1D ). No significant differences were observed in the expression of the IL-23R complex by T cells and NK cells from CLL cases classified as IL-23R-positive or IL-23R-negative (see Fig. 1 ).
The study of IL-23R expression was extended to the PBMCs of an additional 209 CLL patients in the trial. The variability of IL-23R chain expression (median percentage expression, 26%; range, 3.9 to 91.2) (Fig. 1E ) allowed stratification of patients into two groups designated as IL-23R high (≥23%, n = 152) or IL-23R low (<23%, n = 114), based on receiver operating curve (ROC) analysis (as described in Materials and Methods). Notably, IL-23R chain expression was significantly correlated only with immunoglobulin heavy chain variable region (IGHV) gene mutational status (P = 0.049) when considered together with other prognostic markers (table S1) .
Clinical information was available for 219 cases, and we could explore a possible correlation between IL-23R chain expression by CLL cells and time to first treatment (TTFT). Of these cases, 63 met the more recent diagnostic criteria of clinical monoclonal B lymphocytosis (MBL) (27, 28) . The median follow-up was 36 months (range, 6 to 63 months); 8 of 97 IL-23R low and 26 of 122 IL-23R high CLL cases progressed and required treatment. The 3-year TTFT probability of IL-23R low patients was 91.6% compared to 85.0% of IL-23R high cases (Fig. 1E) . Univariate Cox analysis showed that CD38-positive, IGHV gene-unmutated, zeta chain-associated protein kinase 70 (ZAP-70)-positive cases and patients with a peripheral B lymphocytosis of ≥5000/mm 3 had a higher risk of starting treatment compared to CD38-negative, IGHV gene-mutated, ZAP-70-negative, and MBL cases. In a Cox multivariate model, IL-23R chain expression remained significant [hazard ratio (HR) = 2.8, 95% confidence interval (CI) = 1.2 to 6.5, P = 0.014] in predicting TTFT, together with IGHV gene mutational status and B lymphocytosis ≥5000/mm 3 (Fig. 1F) . The same analysis carried out by a bootstrapping Cox regression model provided similar results (table S2) .
Complete IL-23R complex expression is dependent on the CLL tissue microenvironment Next, we investigated whether the uncoupled expression of the two chains of the IL-23R complex also characterized CLL cells within the tissue microenvironment. First, we evaluated the expression of the IL-23R chain in tissue samples from 16 CLL patients, collected at diagnosis using in situ immunolocalization analyses. A variable expression of the IL-23R chain was observed in CLL lymph node (LN) infiltrates, which comprised cases with few scattered IL-23R chainexpressing cells intermingling with a majority of IL-23R chain-negative elements (10 of 16 cases) ( Fig. 2A, left) and cases with a prominent IL-23R chain expression in the majority of the lymphoid infiltrates (6 of 16) ( Fig. 2A, right) . The large majority of IL-23R chain-expressing cells also expressed CD20 (Fig. 2B, left) . IL-12R1 was present within LN infiltrates of IL-23R chain-positive CLL cases, and its expression mainly characterized CD20-positive CLL cells (Fig. 2B, right) . Double-marker IF analysis showed that IL-12R1 expression was not homogeneous, being highly expressed and colocalized with the IL-23R chain in some areas of the LN infiltrates or barely expressed in other LN areas despite a high IL-23R chain staining (Fig. 2C) . Double-marker IF analyses revealed that, within CLL nodal infiltrates, those areas showing dense macrophage infiltration or higher CD40L expression also corresponded to areas with higher IL-12R1 expression (Fig. 2, D 
and E).
Costimulatory signals modulate in vitro IL-12R1 chain expression in CLL Next, we analyzed whether CLL cell activation resulted in upregulation of either IL-23R or IL-12R1 or both receptors. First, we cocultured purified CLL cells in the presence of a CD40L-expressing murine NIH-3T3 cell line (CD40L-TC) or with control cells stably transfected with the plasmid internal ribosomal entry site (pIRES) vector alone (Mock) (29) . After 24 to 48 hours of culture, we found a slight, although significant, induction of the IL-23R chain and a significant up-regulation of IL-12R1 expression in both IL-23R high and IL-23R low cases (Fig. 3A) . Figure 3B summarizes data from 13 CLL cases (3 of 13 being IL-23R low before culture; table S3). In all cases, up-regulation of the IL-23R complex was observed, together with the induction of the IL-12R1. Overall, these phenomena were more marked in the CLL cases classified as IL-23R high . These data were corroborated by the observation of an increased production of IL-12R1 mRNA by stimulated CLL cells (see fig. S2 ).
The IL-23R complex expression was similarly induced upon culturing PBMCs from CLL patients in the presence of CD3/CD28 beads and IL-2 (Fig. 3, C and D) . Under these conditions, autologous T cells present in the suspensions were activated and could, in turn, activate CLL cells. At the end of the culture, the cells were analyzed by flow cytometry. Only viable cells were gated, and the CLL cells present in the suspension were identified as CD5 +
CD19
+ cells. This gated CLL cell population was evaluated for the expression of the IL-23R complex (Fig. 3C) . To demonstrate that IL-23R complex up-regulation was not simply due to a selection of preexisting IL-23R complexpositive subclones, PBMCs from CLL patients were depleted of IL-23R complex-positive cells using immunomagnetic separation beads (Fig. 3I ).
CLL cells produce IL-23 in vivo and in vitro
Subsequently, we investigated the presence of IL-23 in LN tissue specimens from CLL patients. There were two groups of LNs, that is, those that were strongly IL-23-positive (Fig. 4A , left) and those that were almost IL-23-negative (Fig. 4A, right) . This distribution was similar to that already shown for IL-23R (see Fig. 2A ).
There was a clear correlation between the presence of IL-23R and IL-23 in the same infiltrated tissue areas (as shown in Fig. 4B ).
A definite increase of IL-23 secretion was observed in CLL cell supernatants after priming with CD40L-TC (n = 18) or activated autologous T cells (n = 7) (Fig. 4, C and D) . Finally, the CLL cells that expressed the IL-23R complex upon in vitro activation with CD40L-TC were also those that contained abundant intracytoplasmic IL-23 chains as assessed by flow cytometry (see fig. S4 ). IF microphotographs are representative of analyses on at least 5 for low-power magnification (×100) or 10 for high-power magnification (×200 and ×400) microscopic fields performed on each lymph node sample.
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Collectively, these data suggest that the CLL microenvironment elicits an autocrine/paracrine loop involving IL-23R complex up-regulation and IL-23 synthesis. Notably, in vitro IL-23 production could be induced in all CLL clones irrespective of whether they were initially classified as IL-23R high or IL-23R low .
IL-23R complex expression is minimally induced or not induced after coculture of CLL cells with stromal cells or nurse-like cells or after BCR cross-linking
We evaluated whether coculture of CLL cells with stromal cells or nurselike cells (NLCs) results in the induction of IL-23R complex expression. Coculture with the HS5 stromal cell line enhanced IL-23R complex expression by CLL cells, although the observed increase was lower than that obtained by cocultures with CD40L-TC or with activated T cells.
In contrast, there was no significant upregulation of the IL-23R complex after coculture of CLL cells with NLCs. Consistent with this is the observation that HS5 stromal cells and NLCs were CD40L-negative [ fig. S5 and (30)]. However, when PBMCs of CLL patients, rather than highly purified CLL cells, were cocultured with NLCs, there was an up-regulation in the expression of the IL-23R complex ( fig. S6 ).
As expected from previous data (30) (31) (32) , there was an inhibition of spontaneous CLL cell apoptosis in both culture conditions. The data are summarized in fig. S7 . No significant release of IL-23 cytokine (mean ± SEM) was detected in the culture supernatants of CLL cells cultured with medium or with autologous NLC for 7 days (n = 4 CLL cases, 6.44 ± 0 pg/ml versus 1.46 ± 0 pg/ml, respectively) or for CLL cells cultured with medium or with HS5 stromal cells for 72 hours (n = 8 CLL cases, 6 ± 1.2 pg/ml versus 3.6 ± 1.6 pg/ml, respectively), which led us to the conclusion that the IL-23R complex/IL-23 loop was not activated under these culture conditions.
We also investigated whether BCR stimulation of purified CLL cells could induce IL-23R complex expression. We also investigated whether the BCR pathway was involved when CLL cells were induced to express the IL-23R complex by contact with CD40L-TC. To this end, purified CLL cells were incubated with the BTK inhibitor ibrutinib (1 M) 1 hour before coculturing with CD40L-TC or mock cells ( fig. S8 ). After ibrutinib exposure, the IL-23R complex was still detectable, although on a smaller percentage of cells ( fig. S8C ). This treatment caused inhibition of pBTK and decreased cell viability, as shown in fig. S8 (D and E) .
IL-23 acts as a growth factor for CLL cells
Next, we investigated whether IL-23 could facilitate survival and expansion of activated CLL cells in culture. PBMCs from CLL patients were exposed to CD3/CD28 beads for 120 hours in culture, and the CLL cells were subsequently separated from T cells by negative selection using an EasySep Human B Cell Enrichment Kit and then recultured in the presence or absence of IL-23 for an additional 48 hours. A significantly increased viability and a higher Ki67 expression were observed in IL-23-treated CLL cells compared to control cells not exposed to IL-23 ( Fig. 5, A and B) . Addition of IL-23 neutralizing mAb (IL-23p19) to CLL cultured alone resulted in decreased cell viability and proliferation, indicating that there was a production of IL-23 in the culture acting in an autocrine/paracrine manner. This effect of IL-23p19 was largely inhibited by the addition of exogenous IL-23, indicating that the antibody was indeed neutralizing the endogenously produced IL-23. In a subsequent series of experiments, purified CLL cells were activated by coculturing with CD40L-TC for 72 hours and then exposed to small interfering RNAs (siRNAs) specific for IL-23A mRNA and IL-23R mRNA or to negative control siRNAs (see Supplementary Materials and Methods). As apparent from fig. S9 , which shows the results of one representative experiment of three carried out on different cases, treatment with the appropriate siRNAs, but not with the control siRNAs, caused inhibition of IL-23 and IL-23R mRNA production, inhibition of IL-23R expression, and reduction of cell viability and proliferation. Different intracellular kinase inhibitors were added to purified CLL cells cultured with IL-23 after a preactivation step with stimulated autologous T cells. As shown in Fig. 5 (C and D) , ibrutinib treatment had virtually no effect on cell viability and proliferation, whereas tofacitinib [a pan-Janus kinase (JAK) inhibitor] and ruxolitinib (a specific JAK1/2 inhibitor) were effective in decreasing cell viability and particularly cell proliferation. The inhibitory kinase effect was also exerted in the presence of exogenous IL-23.
We further investigated the presence of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and pBTK proteins after exposure of activated CLL cells to IL-23. pSTAT3 (but not pBTK) increased after cell exposure to IL-23 (Fig. 5E) , and phosphorylation persisted in the cultured cells up to 48 hours (Fig. 5H) . BTK was phosphorylated upon stimulation of purified CLL cells with G-Ab or G-Ab (anti- antibody) or with a combination thereof, providing an effective positive control (Fig. 5F ). The preactivation step of CLL cells in culture with activated T cells caused an up-regulation of pSTAT3, which was rather heterogeneous and case-dependent (typical examples of this phenomenon are shown fig. S10 ). This pSTAT3 up-regulation produced a sort of background noise in the cells cultured in the absence of IL-23, which is visible in Fig. 5  (G and I) . However, the levels of pSTAT3 in the preactivated cell cultures when reexposed to IL-23 were consistently higher (Fig. 5,  G and I) . Furthermore, there was a marked inhibition of pSTAT3 detected by flow cytometry when preactivated CLL cells were cultured with IL-23 in the presence tofacitinib and ruxolitinib (Fig. 5, J and K). Under these conditions, ibrutinib was ineffective on pSTAT3 signals, although it had some effect on pBTK. Collectively, these data support the notion that the JAK/STAT pathway was primarily involved in IL-23 signaling to CLL cells and in sustaining cell proliferation in vitro.
IL-23R complex expression is up-regulated in CLL cells growing in NSG mice
Next, we investigated whether the costimulatory signals inducing up-regulation of the IL-23R complex by CLL cell in vitro could be functionally recapitulated by tissue microenvironment signals in vivo. PBMCs from an IL-23R low CLL case (PM608; Fig. 6A ) were inoculated into NOD/Shi-scid,cnull (NSG) mice (34) . Eight weeks after cell injection, mice were sacrificed, and spleen and liver were analyzed for CLL cell infiltration (Fig. 6, B to D) . Neoplastic cell infiltrates, highlighted by human CD20 immunoreactivity, were found in association with patient-derived T cells, identified mainly as human CD4
+ and, to a lesser extent, human CD8 + cells (Fig. 6B) . Moreover, within splenic and hepatic infiltrates, CLL cells showed a high proliferative rate, as suggested by double-marker immunostaining for human CD20 and Ki67 (Fig. 6C) . CD20-positive xenografted CLL cells, which expressed low levels of both IL-23R and IL-12R1 chains at baseline, showed consistent up-regulation of both chains of the IL-23R complex within murine splenic and hepatic infiltrates (Fig. 6C) . Coexpression of IL-23R and IL-12R1 chains was confirmed by flow cytometry (Fig. 6D) . Notably, double-marker confocal microscopy analysis and flow cytometry showed that CLL cells also synthesized IL-23 within murine tissue infiltrates (Fig. 6, E and F) . Similar immunohistochemical patterns of staining for IL-23R complex were observed in three additional xenografting experiments using PBMCs derived from three CLL cases with different baseline levels of IL-23R expression [ZC0010 (8.1%), MG0248 (19.5%), and CD0310 (23.7%); fig. S11 ]. Table S4 reports the features of the cells from different CLL cases (n = 22) used throughout this study; immunohistochemistry (IHC) patterns of CLL cell infiltration similar to those described above were observed in mice xenografted with CLL cells from different cases and with different characteristics. Engraftment was measured by determining the IHC index, derived from the combination of size and numbers of CD20-positive follicles in the spleen [see (35) , the Supplementary Materials, and Materials and Methods]. Engraftment capacities of the different CLL clones in NSG mice were similar regardless of whether they were classified as IL-23R high or IL-23R low .
Interruption of the IL-23R/IL-23 loop has therapeutic effects in vivo
We next investigated the in vivo effect of IL-23p19 mAb-based treatment (36) . Eighteen NSG mice were xenografted with circulating PBMCs from three different CLL cases (PA0146, GA0626, and GE1-BA101, which were xenografted in 4, 4, and 10 mice, respectively). After 4 to 6 weeks, all mice showed leukemia engraftment, based on the flow cytometry detection of circulating human CD45
+ cells. At this point, mice were treated either with one dose of an anti-human IL-23p19 mAb or with the isotype control antibody in each of the days indicated in Fig. 7A . The amount of CLL cells detected in different compartments, evaluated 3 days after the last treatment, was significantly higher in mice treated with the isotype control compared with mice treated with the IL-23p19 mAb, irrespective of tissues where the analysis was performed (Fig. 7B) . Moreover, IHC analysis of human CD20-expressing CLL cells showed that mice treated with the neutralizing IL-23p19 mAb were virtually free of disease infiltration and presented a few cells containing human IL-23 compared to controls (Fig. 7, C and D) . In the spleen of mice freed of the disease after treatment, foci of stromal remodeling indicative of former parenchymal infiltration could be detected morphologically (Fig. 7, C and D) . Notably, mice treated with IL-23p19 mAb showed increased apoptosis in CLL cells (Fig. 7 , E and F) as compared with isotype control-treated mice. Consistently, in mice treated with IL-23p19 mAb, there was a decrease of Ki67-positive CLL cells as assessed by double-marker IF and flow cytometry analyses on spleen infiltrates (Fig. 7, G to I) . Notably, molecular testing for the specific BCR rearrangement of the CLL clone Microphotographs are representative of analyses on at least 10 for high-power magnification (×200 to ×630) microscopic fields performed on each mouse spleen tissue sample.
of the donor patient was identified in different compartments of control antibody-treated mice and was not detected in mice achieving a complete remission as determined by flow cytometry evaluation ( fig. S12 ). The striking effect of IL-23p19 mAb treatment does not appear to be attributable to opsonization of CLL cells by IL-23p19 mAb, which, in principle, could recognize the IL-23 bound to activated CLL cells. The cells so opsonized could be subsequently killed by antibody-dependent cell-mediated cytotoxicity or complement activation. This conclusion stems from the observation of very few human CD16-positive cells in the proximity or within leukemic nodules in NSG mice ( fig. S13A ). Moreover, CLL cells activated in vitro by coculture with activated T cells and exposed to IL-23 failed to bind IL-23p19 mAb ( fig. S13B ) and to fix complement ( fig. S13C) .
In an independent set of in vivo experiments, we investigated whether IL-23p19 mAb treatment could be effective in achieving a durable response in mice with rapidly progressive disease. Given that experiments in mice could not be prolonged for longer than 9 weeks because of possible excessive animal suffering, the experiments were designed as follows: 12 mice were injected with a higher number of PBMCs (100 × 10 6 cells per mouse) from CLL case SD36 (6 mice) or CLL case GE2-RL201 (6 mice) to obtain a more rapid engraftment with a high leukemic burden. Two weeks after cell injection, the average percentage of circulating leukemic cells (human CD45 + CD19 + CD5 + cells) in the 12 mice was 73.4 ± 2.6%. At this time point, therapy was administered with the same schedule described above (Fig. 7A) : Six mice received IL-23p19 mAb (4 doses) and the other six received the isotype control mAb. Three weeks from the last mAb dose, mice were sacrificed, and IHC on spleen tissue sections was carried out (Fig. 8, A and B) . CLL cells were also measured in the spleen, liver, bone marrow, and PBMCs by flow cytometry (Fig. 8C) . The administration of a high number of leukemic cells caused the appearance of larger and more numerous infiltration foci in the mice spleen parenchyma, as observed by IHC for human CD20 staining. These foci were substantially reduced in number and size after IL-23p19 mAb treatment. The actual relation of the infiltration foci with the CLL clones was documented by IGHV gene rearrangement analysis (Fig. 8, A and B, insets) . The number of CLL cells infiltrating the different tissues was largely reduced in the IL-23p19 mAb-treated mice compared to controls at all sites tested by flow cytometry (P = 0.03, Wilcoxon test) (Fig. 8C ).
DISCUSSION
We have identified an autocrine/paracrine loop represented by the IL-23 complex expression and IL-23 production necessary for the clonal expansion of CLL cells ( fig. S14) . Inhibition of this loop with the appropriate mAb resulted in impaired viability and incapacity for CLL cell proliferation in vitro and prevented expansion of the leukemic clones in NSG mice with a prolonged remission of the disease. Therefore, the IL-23R/IL-23 axis may represent a suitable target for CLL treatment.
The expression of the IL-23R complex and particularly of the "limiting" IL-12R1 chain was dependent on interactions with microenvironmental elements, as demonstrated by in vitro studies and corroborated by in situ observations on LN tissue sections showing the proximity between activated, IL-23R complex-expressing CLL cells with stromal macrophages and other CD40L + cells. These data are also in line with observations in NSG mice, indicating that activated/proliferating Ki67 + CD38
+ CLL cells were also capable of expressing the IL-23R complex in vivo.
Expression of the IL-23R complex appears to be a multistep process, characterized by the initial expression of the IL-23R and, subsequently, by that of the IL-12R1. The progressive expression of these structures may be regulated by the cell activation status. CLL clones appear to be frozen at two particular stages: no receptor expression (IL-23R low CLL) or expression of the IL-23R only (IL-23R high CLL). The IL-23R low and IL-23R high phenotypes also distinguish two patient groups with different clinical features. Higher activation of IL-23R high CLL clones may in part explain the more aggressive disease progression. Whether this stepwise process of IL-23R complex expression also characterizes the activation process of normal B cells and their response to IL-23 is presently unknown. However, the hypothesis that CLL cells have a genetic defect, either germ line or somatic, which prevents a complete IL-23R complex expression (37) , was ruled out by a number of observations, including the fact that IL-23R complex expression can be induced on CLL cells from both (IL-23R high and IL-23R low ) groups of patients in vitro and in NSG mice and that substantial expression of IL-23R complex was observed in the NK cells and T cells of the same CLL patients.
The IL-23R complex/IL-23 loop was not induced by coculturing CLL cells with stromal cells or NLCs. Because both cell types do not express CD40L, these observations stress the requirement for a CD40L/ CD40 interaction in the activation of this autocrine/paracrine loop. Notably, the failure of NLCs and stromal cells to activate this loop was observed only when highly purified CLL cells (and not total PBMCs from the patients) were used in the coculture systems, indicating that the few activated T cells or other CD40L-expressing cells remaining in the PBMCs were sufficient to sustain IL-23 production and IL-23R complex expression. The involvement of the CD40/CD40L interactions is also supported by the observation that BCR stimulation was unable to activate the IL-23R complex/IL-23 loop, even in the presence of IL-4 (33, 38) , although BCR-derived signals may exert a regulatory role. For example, ibrutinib caused some inhibition of the IL-23R complex induction in vitro in CLL cells activated via CD40L stimulation. Because there was a concomitant diminution of cell viability, this was likely related to the inhibition of the trophic effect normally exerted by BCR on B cells (39, 40) . This inhibition of BCRdelivered trophic signals is likely to be responsible for most of the reduction of CLL cell clonal expansion caused by ibrutinib in NSG mice (41) .
Signals of the IL-23R complex after binding to IL-23 are delivered via STAT3, as documented by the observation that exposure of activated CLL cells to IL-23 caused pSTAT3 increase as in previous studies (22, 42) and that this pathway was susceptible to the effect of JAK/ STAT inhibitors and was resistant to ibrutinib. Therefore, the JAK/ STAT pathway may represent an additional therapeutic target for CLL, independent of the BCR pathway.
IL-23 released by CLL cells may affect the patient T cell subset population composition and function, given its effects on T cells ( fig. S14) (43) . These considerations may help explain abnormalities in T cell composition reported both in patients and in experimental animals with CLL-like disease (44) . IL-23 may facilitate the expansion of certain T cell subsets, instrumental in promoting CLL clonal expansion. The absence of this T cell support in NSG mice exposed to a neutralizing anti-IL-23 antibody would provide an explanation for the efficiency of the treatment in eradicating the engrafted leukemic clone. This hypothesis seems to be preferable to that of a direct cytotoxicity of IL-23p19 mAb on CLL cells growing in NSG mice.
Together, the above observations indicate that the activation of the IL-23R complex/IL-23 loop depends on a number of variables including CLL cell contact with CD40L-expressing cells, JAK/STAT pathway activation, and T cell composition. Moreover, these factors require particular trafficking conditions in peripheral lymphoid tissues, to efficiently exert their function, as documented by the heterogeneity of neoplastic cell distribution in the LNs and the relationship of these cells with different microenvironmental cell components. Given these considerations, it is not surprising to find different degrees of CLL activation among cell clones from different patients or to observe differences in the plasma levels of IL-23 as reported in another study (45) . Unfortunately, such determination could not be performed in the present cohort because of the lack of sera availability. Reevaluation of IL-23 mRNA levels in the circulating CLL cells from the patient cohort of this study, obtained from a previous gene expression profile investigation (28) , revealed no correlation between the mRNA levels and the classification of a case as IL-23 high or IL-23 low , or the presence of unfavorable prognostic markers, possibly reiterating the concepts that the events occurring in peripheral lymphoid organs are the most relevant in determining the activation of the IL-23R complex/IL-23 loop, the levels of plasma IL-23, and perhaps the patient's clinical course.
Inconsistent with the present observations are studies in different lymphoproliferative disorders that have reported either an inhibitory effect of IL-23 on the growth of the neoplastic cells (DLBCL, FL, and ALL) or no effect (myeloma) (23) (24) (25) (26) . The reasons for these discrepancies are presently obscure. Tentatively, one could speculate that cells from different neoplasms could respond differently to IL-23 exposure, owing to differences in activation status in vivo.
The in vivo xenograft experiments demonstrated the effective dependence of IL-23R complex regulation by the tissue microenvironment. Notably, we did not find any differences in CLL cell engraftment in NSG mice of clones classified as either IL-23 high or IL-23 low . This observation may have two non-mutually exclusive explanations: (i) that engraftment was greatly facilitated not only by the presence of the patient T cells but also by their preactivation step with CD3/CD28 beads and IL-2 to which all CLL PBMC suspensions are routinely subjected before inoculation in our laboratory, or (ii) that the murine environment represented a suitable milieu for the full activation of the IL-23R complex/IL-23 loop. The present experiments demonstrated the efficacy of a mAb-based interference of the IL-23R/IL-23 axis in CLL disease control and eradication. The use of an IL-23p19 antibody, currently adopted in the clinical setting for the treatment of autoimmune diseases (46) , represents a strong prospect for the translation of the results from our in vivo animal studies, although they were limited to a single model dependent on immunodeficient mice. This study indicates that the JAK/STAT pathway may represent an additional suitable therapeutic target for CLL, as in diseases characterized by IL-23-driven lymphocyte proliferation. Thus, an anti-IL-23 mAb and JAK/STAT inhibitor alone or in combination may represent a future tool for the treatment of a disease that, so far, appears to be incurable (47, 48) .
MATERIALS AND METHODS
Study design
The aim of this work was to determine the role of the IL-23R/IL-23 autocrine loop in CLL clonal survival/expansion and to ascertain whether this loop is drug-targetable. This study was generated by the observation that cells from CLL clones can express different levels of IL-23R and that CLL cases classified as IL-23R high have a shorter TTFT than cases classified as IL-23 low . Therefore, IL-23R could conceivably be part of a series of events leading to clonal expansion. To investigate this hypothesis, we first studied whether a fully functional IL-23R complex could be induced on CLL by a number of stimuli. CLL cells from both IL-23 high and IL-23 low patient groups expressed IL-23R complex and began to secrete IL-23 when activated in vitro by contact with CD40L-expressing cells. This activation process was accompanied by increased cell viability, by decreased spontaneous apoptosis, and by cell proliferation. To investigate whether this CD40L-mediated activation process also occurred in vivo, we first observed LN from CLL patients by IHC and found that IL-23R complex-expressing and IL-23-secreting CLL cells were located primarily at sites enriched of CD40L + cells. To further investigate the potential role of an IL-23R complex/IL-23 autocrine/paracrine loop, we inoculated the CLL cells into NSG mice together with activated autologous T cells. Groups of these mice were treated with a neutralizing IL-23p19 mAb, whereas control mice received an irrelevant mAb. IL-23p19 mAb-treated mice displayed a substantial inhibition of CLL cell growth compared to control mice. In situ studies showing IL-23 production as well as IL-23R complex expression particularly at the site of CLL cell growth expansion confirmed this notion.
Data are presented as mean ± SEM or mean ± SD, which were calculated invariably from n (the number of patients or animals, biological replicates). Primary data are reported in table S5.
Statistical analysis
The statistical software package SPSS for Windows, v.13.0, 2004 (SPSS UK), was used for all analyses. For categorical variables, statistical comparisons were performed using two-way tables for Fisher's exact test and multiway tables for Pearson's chi-square test. Statistical comparisons between related samples were carried out by Wilcoxon or Mann-Whitney U tests.
The best cutoff point for IL-23R expression able to discriminate cases that progressed from those that did not progress was sought by constructing ROCs. TTFT analyses were performed using the Kaplan-Meier method. Statistical significance of associations between individual variables and survival was calculated using the log-rank test. The prognostic impact for the outcome variable was investigated by univariate and multiple Cox regression analysis. Data are expressed as HR and 95% CI. To assess the internal validity of univariate and multivariate Cox regression models, we performed a bootstrap resampling technique of 1000 samples (49) . P < 0.05 was considered significant for all statistical calculations. Values are given as mean ± SEM or mean ± SD.
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